European Equities Traded in the US as ADRs Rise in Tuesday Trading

MT Newswires Live04-14 23:05

European equities traded in the US as American depositary receipts rose late Tuesday morning with the S&P Europe Select ADR Index gaining 0.3% to 1,844.78.

From continental Europe, the gainers were led by biopharmaceutical company Grifols (GRFS) and internet browser company Opera (OPRA), which rose 3.1% and 2.9%, respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and semiconductor company Sequans Communications (SQNS), which were up 2.3% and 1.6%, respectively.

The decliners from continental Europe were led by petroleum refiner Equinor (EQNR) and biotech firm Evaxion (EVAX), which fell 2.5% and 1.2%, respectively. They were followed by oil and gas company Eni (E) and pharmaceutical company Ascendis Pharma (ASND), which were down 1% and 0.5%, respectively.

The gainers from the UK were led by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Biodexa Pharmaceuticals (BDRX), which advanced 6.2% and 4.2%, respectively. They were followed by biopharmaceutical company NuCana (NCNA) and cruise line operator Carnival (CUK), which increased 3.4% and 3%, respectively.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and pharmaceutical company Silence Therapeutics (SLN), which dropped 1.7% and 1.5%, respectively. They were followed by tobacco company British American Tobacco (BTI) and oil and gas company Shell (SHEL), which were off 1.4% and 1.1%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment